# EDGAR Filing Document

**Accession Number:** 0001484565
**File Stem:** 0001614821-26-000002
**Filing Date:** 2026-5
**Character Count:** 8850
**Document Hash:** 5b8b1b036c00f9da91f9effc3d82e86e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001614821-26-000002.hdr.sgml**: 20260518

**ACCESSION NUMBER**: 0001614821-26-000002

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260518

**FILED AS OF DATE**: 20260518

**DATE AS OF CHANGE**: 20260518

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Anish Bhatnagar
- **CENTRAL INDEX KEY:** 0001614821

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36593
- **FILM NUMBER:** 26993910

**BUSINESS ADDRESS:**
- **STREET 1:** C/O SOLENO THERAPEUTICS, INC.
- **STREET 2:** 100 MARINE PARKWAY, SUITE 400
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 650-213-8444

**MAIL ADDRESS:**
- **STREET 1:** C/O SOLENO THERAPEUTICS, INC.
- **STREET 2:** 100 MARINE PARKWAY, SUITE 400
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SOLENO THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0001484565
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 770523891
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 100 MARINE PARKWAY, SUITE 400
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 650-213-8444

**MAIL ADDRESS:**
- **STREET 1:** 100 MARINE PARKWAY, SUITE 400
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Capnia, Inc.
- **DATE OF NAME CHANGE:** 20100219

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Anish Bhatnagar<br><sub>(Last) (First) (Middle)</sub><br>100 MARINE PARKWAY, SUITE 400<br><sub>(Street)</sub><br>REDWOOD CITY, CA 94065<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CHIEF EXECUTIVE OFFICER_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>SOLENO THERAPEUTICS INC [ SLNO ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-05-18 |  | D |  | 583656<sup>(1)</sup> | D | <sup>(2)</sup> | 0 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (Right to buy) | $44.25 | 2026-05-18 |  | D |  |  | 22452 | <sup>(3)</sup> | 2027-04-19 | Common Stock | 22452 | <sup>(3)</sup> | 0 | D |  |
| Employee Stock Option (Right to buy) | $24 | 2026-05-18 |  | D |  |  | 60 | <sup>(3)</sup> | 2028-02-07 | Common Stock | 60 | <sup>(3)</sup> | 0 | D |  |
| Employee Stock Option (Right to buy) | $51.15 | 2026-05-18 |  | D |  |  | 23332 | <sup>(3)</sup> | 2030-05-18 | Common Stock | 23332 | <sup>(3)</sup> | 0 | D |  |
| Employee Stock Option (Right to buy) | $33.60 | 2026-05-18 |  | D |  |  | 35000 | <sup>(3)</sup> | 2031-01-08 | Common Stock | 35000 | <sup>(3)</sup> | 0 | D |  |
| Employee Stock Option (Right to buy) | $5.10 | 2026-05-18 |  | D |  |  | 8473 | <sup>(3)</sup> | 2032-01-28 | Common Stock | 8473 | <sup>(3)</sup> | 0 | D |  |
| Employee Stock Option (Right to buy) | $2.595 | 2026-05-18 |  | D |  |  | 73333 | <sup>(3)</sup> | 2032-07-27 | Common Stock | 73333 | <sup>(3)</sup> | 0 | D |  |
| Employee Stock Option (Right to buy) | $2.41 | 2026-05-18 |  | D |  |  | 52709 | <sup>(3)</sup> | 2033-01-25 | Common Stock | 52709 | <sup>(3)</sup> | 0 | D |  |
| Employee Stock Option (Right to buy) | $5.25 | 2026-05-18 |  | D |  |  | 200753 | <sup>(3)</sup> | 2033-05-26 | Common Stock | 200753 | <sup>(3)</sup> | 0 | D |  |
| Employee Stock Option (Right to buy) | $36.70 | 2026-05-18 |  | D |  |  | 100000 | <sup>(3)</sup> | 2034-01-04 | Common Stock | 100000 | <sup>(3)</sup> | 0 | D |  |
| Employee Stock Option (Right to buy) | $49.17 | 2026-05-18 |  | D |  |  | 115600 | <sup>(3)</sup> | 2035-01-21 | Common Stock | 115600 | <sup>(3)</sup> | 0 | D |  |
| Employee Stock Option (Right to buy) | $43.65 | 2026-05-18 |  | D |  |  | 131400 | <sup>(3)</sup> | 2036-01-21 | Common Stock | 131400 | <sup>(3)</sup> | 0 | D |  |

---

### Footnotes:

(1) Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration").

(2) In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.

(3) At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation.

**Signature:** /s/ Anish Bhatnagar  
**Date:** 2026-05-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**